Cat.No. : CSC-SC002838 Host Cell: HEK293 (CHO and other cell types are also available)
| Cat. No. | CSC-SC002838 |
| Description | Using Creative Biogene's proprietary lentiviral vectors, we subclone the target gene into lentivector, generate the lentivirus particles, sequentially infect the cell line HEK293 (other cell types are also available according to your requirements), and select the clones constantly expressing target gene at high level. |
| Gene | CDH2 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | HEK293 (CHO and other cell types are also available) |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Signaling pathway research 3. Drug screening and toxicology 4. Disease research |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Size Form | 2 × 10^6 cells / vial |
| Shipping | Dry Ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Gene Name | CDH2 cadherin 2, type 1, N-cadherin (neuronal) [ Homo sapiens ] |
| Gene Symbol | CDH2 |
| Synonyms | CDH2; cadherin 2, type 1, N-cadherin (neuronal); NCAD; cadherin-2; CD325; CDHN; N cadherin; N-cadherin 1; neural cadherin; neural-cadherin; cadherin 2, N-cadherin (neuronal); calcium-dependent adhesion protein, neuronal; CDw325; |
| Gene ID | 1000 |
| UniProt ID | P19022 |
| mRNA Refseq | BC036470 |
| Chromosome Location | 18q12.1 |
| Function | RPTP-like protein binding; alpha-catenin binding; beta-catenin binding; calcium ion binding; gamma-catenin binding; protein kinase binding; protein phosphatase binding; |
| Pathway | Adherens junctions interactions, organism-specific biosystem; Arrhythmogenic right ventricular cardiomyopathy (ARVC), organism-specific biosystem; Arrhythmogenic right ventricular cardiomyopathy (ARVC), conserved biosystem; CDO in myogenesis, organism-specific biosystem; Cell adhesion molecules (CAMs), organism-specific biosystem; Cell adhesion molecules (CAMs), conserved biosystem; Cell junction organization, organism-specific biosystem; |
| MIM | 114020 |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Enzalutamide is a treatment option for patients with castration-resistant or metastatic prostate cancer. However, a significant proportion of patients develop resistance after a period of enzalutamide treatment. Cells in these tumors often exhibit enhanced proliferation and migration, with N-cadherin (CDH2) appearing to play a key role. Here, researchers investigated the potential effects of CDH2 on the prostate cancer cell line LNCaP by upregulating and downregulating CDH2 expression. Androgen-sensitive LNCaP cells, designated LNCaP enzalutamide-resistant (EnzaR) cells, were treated with 10 µM enzalutamide. The study found increased CDH2 expression in LNCaP EnzaR cells compared to LNCaP cells. Overexpression of CDH2 enhanced cell viability and migration in both LNCaP and LNCaP EnzaR cell lines. Conversely, inhibition of CDH2 expression exhibited the opposite effect. CDH2 expression was also highly correlated with the expression of four epithelial-mesenchymal transition markers, as confirmed by Western blotting. These results suggest that inhibition of CDH2 expression by siRNA transfection significantly affects the physiology of LNCaP EnzaR cells and may represent a potential therapeutic option for prostate cancer.
MTT assay results showed that cell viability in the CDH2-overexpressing LNCaP cell line was higher than in the other two control groups (Figure 1). Similar results were observed in the LNCaP EnzaR cell line (Figure 1A). Next, cell viability in the LNCaP and LNCaP EnzaR cell lines was assessed using the CCK-8 assay. Twenty-four hours after transfection, cell viability in the CDH2-overexpressing LNCaP and LNCaP EnzaR cell lines was also higher than in the other two control groups (Figure 1B). These results indicate that CDH2 overexpression can enhance PCa cell viability.
Figure 1. Overexpression of CDH2 increases LNCaP and LNCaP EnzaR cell viability. (Lu C H, et al., 2022)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
